Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma
JAMA Dermatology · 01.09.2025 · 161 (9) · 923
DOI: 10.1001/jamadermatol.2025.1926 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift JAMA Dermatology, erschienen am 01.09.2025. Verfasst von Zhiyu Pang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medica…. Hauptthemen laut MEDLINE: Aminopyridines, Lymphoma, T-Cell, Cutaneous, Antineoplastic Combined Chemotherapy Protocols, Benzamides. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Patients with relapsed or refractory (r/r) cutaneous T-cell lymphoma (CTCL) have limited treatment options. Combining agents that target complementary oncogenic pathways may enhance efficacy while maintaining tolerability.
Objective
To evaluate the safety and efficacy of linperlisib, a PI3Kδ inhibitor, combined with chidamide, a histone deacetylase inhibitor, in patients with r/r CTCL. Design, Setting, and Participants This prospective, single-arm, phase 1 nonrandomized clinical trial with a 3 + 3 dose-escalation phase followed by dose expansion was conducted at a tertiary referral hospital in China from May 1, 2023, to March 6, 2025, with a median follow-up of 8.9 months (range, 1-21 months). It included patients with histologically confirmed advanced CTCL. All had an Eastern Cooperative Oncology Group performance status of 0 to 2 and received a median (range) of 3 (1-7) prior systemic therapies. Patients were enrolled consecutively based on eligibility.
Interventions
Oral linperlisib administered once daily in escalating doses (40 mg, 60 mg, or 80 mg) plus chidamide, 20 mg, twice weekly. Treatment continued until progression, unacceptable toxic effects, or withdrawal. Main Outcomes and Measures Primary outcomes were dose-limiting toxic effects, maximum tolerated dose, and objective response rate. Secondary outcomes included safety, progression-free survival, and disease control rate.
Results
Of 22 patients (19 [86.4%] with mycosis fungoides, 3 [13.6%] with Sézary syndrome), 10 were female individuals (45.5%), and the median (range) age was 44 (27-71) years. No dose-limiting toxic effects were observed. The recommended phase 2 dose of linperlisib was 80 mg. The most common treatment-related adverse events were nausea (8 [36.4%]), pruritus (7 [31.8%]), and skin rash (6 [27.3%]), mostly grade 1 to 2. Grade 3 adverse events occurred in 5 patients (22.7%); no grade 4 to 5 events were reported. The objective response rate was 59.1% (13 of 22; 95% CI, 38.7%-76.7%), including 2 complete responses and 11 partial responses. The disease control rate was 86.4% (19 of 22), and the median progression-free survival was 5.4 months. Conclusions and Relevance This nonrandomized clinical trial found that plus chidamide showed a manageable safety profile and promising activity in r/r CTCL. This all-oral combination may represent a new therapeutic option for advanced CTCL, particularly in mycosis fungoides. Trial Registration ClinicalTrials.gov Identifier: NCT06037239
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Researc…
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Tsinghua Medicine, School of Medicine, Tsinghua University, Beijing, China.
Zitieren
APA
Pang, Z., Wang, Y., Liu, Z., Zhang, S., Wei, C., Xu, Z., Wang, Z., Chen, H., Liu, J., & Zhang, W. (2025). Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma. JAMA Dermatology, 161(9), 923. https://doi.org/10.1001/jamadermatol.2025.1926
Vancouver
Pang Z, Wang Y, Liu Z, Zhang S, Wei C, Xu Z, et al. Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma. JAMA Dermatology. 2025;161(9):923. doi:10.1001/jamadermatol.2025.1926
BibTeX
@article{Pang2025,
author = {Pang, Zhiyu and Wang, Yupeng and Liu, Zhaorui and Zhang, Shan and Wei, Chong and Xu, Zhuofan and Wang, Ziqian and Chen, Hongyun and Liu, Jie and Zhang, Wei},
title = {Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma},
journal = {JAMA Dermatology},
year = {2025},
volume = {161},
number = {9},
pages = {923},
doi = {10.1001/jamadermatol.2025.1926}
}
EUVIMED